





# Troubleshooting and Engineering of Antibody Constructs - part II



# Engineering of full-length IgG



## Variable region


Objectives of Engineering	Strategies of Engineering
To modulate Antigen binding affinity or specificity	<ul style="list-style-type: none"> <li>• Random mutation in CDRs and high throughput screening</li> <li>• Rationale design in CDRs</li> </ul>
To reduce immunogenicity	<ul style="list-style-type: none"> <li>• Humanization or dehumanization of framework regions</li> </ul>
To decrease elimination of IgG	<ul style="list-style-type: none"> <li>• Mutation of variable region to lower the isoelectric point</li> </ul>

## Fc region

Objectives of Engineering	Strategies of Engineering
To alter effector functions (ADCC, ADCP and CDC)	<ul style="list-style-type: none"> <li>• Sequence alteration in Fc region</li> <li>• Modified glycosylation (non fucosylation, Aglycosylation)</li> </ul>
To improve an anti-inflammatory activity	<ul style="list-style-type: none"> <li>• Introduction of sialylated glycans</li> </ul>
To alter half-life (pharmacokinetic)	<ul style="list-style-type: none"> <li>• Sequence alteration in Fc regions (FcRn binding region)</li> </ul>
To construct antibody based drugs or toxins To label a radioisotope	<ul style="list-style-type: none"> <li>• Fc fusion to target molecules</li> <li>• Introduction of Cys residue</li> </ul>





# Are previous findings transferable?



# Analytical challenge: Multidomains

- ➔ IgGs consist of six individual domains (each in duplicates), all having similar folds




- ➔ with most experimental setups, only **overall average** of biophysical features will be analyzed





# Biophysical analyses (methodology)

## Circular Dichroism (CD)




(2<sup>ry</sup> structure composition)

thermal denaturation

(aggregation analysis)



## Intrinsic Tryptophan Fluorescence (ITF)



thermal denaturation

chemical denaturation

## Differential scanning calorimetry / fluorimetry



analysis of individual domains




# Circular Dichroism (CD)

Lambert-Beer derivative:  $\Delta A = A_L - A_R = \epsilon_L \times l \times C - \epsilon_R \times l \times C = \Delta\epsilon \times l \times C$

ellipticity:  $\theta = \frac{2.303 (A_L - A_R)}{4l}$

MRE:  $[\theta] = \frac{\theta \times 100 \times M}{C \times l \times n}$


**amide chromophore** of peptide bond has 2 electronic transitions of low energy:  
 $n \rightarrow \pi^*$  (signals at 222 nm and 215 nm) and  $\pi \rightarrow \pi^*$  (signals at 208 nm and 198 nm)





- ➡ at ~ 208 nm intensity due to β-sheets is essentially zero
- ➡ measuring ellipticity at 208 nm monitors **changes in structure** (negative shift caused by random coil formation)



# CD: real examples



➔ unfolding detectable, however sheaded by aggregation





Trp fluorescence is very sensitive to local conformation and environment

Quantum yields:

Phe - 0.02

Tyr - 0.13

Trp - 0.12

IgG 2C2: 24 Trp per IgG

IgG 6B3: 26 Trp per IgG

**IgG 6B3**

Domain	# of Trp	% of all Trp
V <sub>H</sub>	5	38.5
CH <sub>1</sub>	1	7.7
CH <sub>2</sub>	2	15.4
CH <sub>3</sub>	2	15.4
V <sub>L</sub>	1	7.7
CL	2	15.4

**IgG 2C2**

Domain	# of Trp	% of all Trp
V <sub>H</sub>	5	41.7
CH <sub>1</sub>	1	8.3
CH <sub>2</sub>	2	16.7
CH <sub>3</sub>	2	16.7
V <sub>L</sub>	1	8.3
CL	1	8.3

➔ majority of Trp residues are located within V<sub>H</sub> domain








Trp fluorescence is very sensitive to local conformation and environment

wavelength maximum shifts upon heating due to changes of polarity in vicinity of Trp (**red-shift** of Trp emission spectrum)

red shift can be monitored by ratio of intensities at 330 and 350 nm





**benefit over other methods:**

- aggregation doesn't cover unfolding reaction
- can easily be performed in plate reader





# ITF: real examples

## Temperature-unfolding




## GdnHCl-unfolding






# Real-time GdnHCl denaturation


HEK IgG 6B3 WT




HEK IgG 6B3 M



HEK IgG 2C2 WT




HEK IgG 2C2 M





# Differential Scanning Fluorimetry (DSF)



melting temperature detected by increased fluorescence of dye with **affinity for hydrophobic parts of the protein**



Sypro-Orange (Molecular Probes)





in aqueous solution: **quenched fluorescence;**  
**highly fluorescent in non-polar environment**

relatively **high excitation wavelength**  
decreases likelihood of small molecules  
interfering with optical properties of dye,  
causing quenching of fluorescence intensity






# DSF: real examples





## Power-compensation DSC (not Heat-flux DSC)



continuously self-adjustment  
of heating power for keeping  
sample and reference at same  
temperature

difference of required power  
[J/sec] divided by the scan  
rate [°C/sec] leads to heat  
capacity [J/°C]

Integration of heat capacity vs. temperature yields the enthalpy ( $\Delta H$ )




$$\Delta H = \int_{T_1}^{T_2} C_p dT$$

$$\Delta G = \Delta H - T \cdot \Delta S$$

(Gibbs Free Energy equation)



# DSC: real examples



➡ DSC is only setup detecting small differences of very stable transition





# VP-DSC vs. VP-Capillary DSC



plate storage

autosampler









# VP-DSC vs. VP-Capillary DSC

	VP-DSC	VP-Capillary DSC
analyzed volume	510 $\mu\text{l}$	130 $\mu\text{l}$
sample volume	1'200 $\mu\text{l}$	400 $\mu\text{l}$
scan rates	0.5 - 1.5 $^{\circ}\text{C}/\text{min}$	0.16 - 4 $^{\circ}\text{C}/\text{min}$
sample cell	coin shaped	capillary
samples	1	up to 288
measuring time	1 day	4 hrs
cleaning	manual	automatic

major advances: sensitivity, throughput, reproducibility, stability and ease of use  
(smaller sample requirements)



# VP-DSC vs. VP-Capillary DSC







# Convection at aggregation

protein aggregation: heat signal detected by DSC is sum of both **endothermic unfolding** and **exothermic aggregation**

## convection appears



once sample aggregates, interference and baseline drop

molecules are located in small confined space

## very little convection





due to small diameter of capillaries

molecules are separated with enough space (aggregation delayed)

➔ signals derived from Capillary-DSC are **less sensitive to aggregation**



# Comparison DSF vs. DSC



compared to DSC, DSF lacks "resolution" of individual domains, however is much faster (2-3 hrs vs. 48-72 hrs), can be performed in parallel and requires much less protein (20  $\mu\text{g}$  vs.  $\sim 1$  mg)



# Stability overview

		ITF	GdnHCl	DSF	DSC
IgG 2C2	WT	70.4°C*	2.5 M	n.d.	86.0°C
	M	71.8°C*	3.8 M	n.d.	87.8°C
		$\Delta = 1.4^\circ\text{C}$	<b>1.3 M</b>	-	<b>1.8°C</b>
IgG 6B3	WT	67.6°C	2.0 M	74.5°C	72.1°C
	M	70.8°C	2.6 M	77.0°C	74.3°C
		$\Delta = 3.2^\circ\text{C}$	<b>0.6 M</b>	<b>2.5°C</b>	<b>2.2°C</b>

\* - determined in presence of 1 M GdnHCl


n.d. - not determined



**IgG stability  
analyses**




**IgG expression  
systems**





# Eukaryotic expression systems


## Mammalian cell culture



stable HEK293 (Flp-In)

CMV promoters (constitutive)

## Yeast *Pichia pastoris*



stable SMD1163 (his4 pep4 prb1)

GAP promoters (constitutive)





## Expression of full-length IgGs in methylotrophic yeast *Pichia pastoris*

### ➔ advantages of expression system:

- disulfide bond formation / isomerization
- posttranslational modification (glycosylation)
- very high cell densities
- high expression levels (up to 30%)

### ➔ different promoters available:



- MeOH-inducible AOX1 (alcohol oxidase 1)
- constitutive GAP (glyceraldehyde-3-phosphate dehydrogenase)

➔ **only low-level secretion of endogenous proteins**, being advantageous for protein purification and downstream processing

➔ **> 50 reports describing antibody expression**  
(mainly scFvs, several Fabs, only handful full-length IgG)


## major difference in expression systems: glycosylation

- ➔ yeast system processes same sugar precursor differently (in Golgi complex), resulting in a **different glycan**






# N-linked glycosylation





# Glyco-engineering of *Pichia*


## *Pichia* GlycoSwitch®: introducing complex, human-like glycosylation






# N-linked glycan processing

HEK293 cells




$\text{Gal}(\text{GlcNAc})_2(\text{Man})_3(\text{GlcNAc})_2\text{Fuc}$

*Pichia pastoris*



$(\text{Man})_{9-10-18}(\text{GlcNAc})_2$







➔ *Pichia* glycan cause difficulties interacting with Fcγ receptors (FcγR) important for effector functions







# Influence of glycosylation on stability

- ➔ *Pichia* produced IgGs have decreased  $C_H2$  stability, compared to mammalian expression
- ➔ different  $C_H2$  stabilities are caused by different glycan moieties






- ➔ *Pichia*-derived glycans reduce aggregation tendency
- ➔ EAEA-peptide (originating from yeast signal sequence) decreases aggregation susceptibility of HEK-IgG upon N-terminal addition




# Signal sequence processing pathways

## *P. pastoris* (PP)



## mammalian cells (HEK)





➔ overexpression often results in **incomplete proteolytic processing**




# EAEA protects against aggregation

## IgG (HEK)





➡ addition of EAEA decreases aggregation propensity

➡ position of EAEA matters:  
larger effect on LC than on HC





accelerated stress conditions (MALS analyses after 5 days)



➔ **decreased aggregation susceptibility** also at lower temperatures and at very low IgG concentrations (1 mg/ml)



# Comparison with published results

➡ solubility of proteins can be enhanced by introducing charged residues (altering the overall charge)

Lawrence *et al.*, *JACS* (2007); Arbabi-Ghahroudi *et al.*, *Protein Eng. Des. Sel.* (2009)

➡ aggregation-resistant  $V_H$  domains /  $V_{HH}$  possess greater negative net charge

Jespers *et al.*, *Nat. Biotechnol.* (2004); Perchiacca *et al.*, *Proteins* (2011)


➡ introduction of negatively charged residues into CDR1 loop reduces aggregation susceptibility (however, other mutations effectless)

Perchiacca *et al.*, *Proteins* (2011)

➡ our approach of N-terminal addition of negative charges does not influence antigen recognition and can easily be performed by cloning



# Producing correctly processed IgG



best combination of **yield and aggregation resistance:**

- for HC: **without** pro-region and **without** EAEA
- for LC: **with** pro-region and **with** EAEA

**native-like IgG** can be made:

- for HC: **without** pro-region and **without** EAEA
- for LC: **with** pro-region and **without** EAEA





## Conclusion full-length IgGs

- advanced stabilities both with respect to thermal and denaturant-induced unfolding can be transferred to other formats, independent of expression system
- increase in structural integrity and homogeneity
- *Pichia pastoris* is an interesting expression system with several benefits (ease of handling, costs, ...)
- optimal sequence composition for either aggregation-resistant or correctly processed IgGs available



# Acknowledgements

## Dept. of Biochemistry, UZH

Andreas Plückthun

Birgit Dreier

Annemarie Honegger

Peter Lindner

all present and former lab members

## Academic partners

Ilian Jelezarov (UZH)

Paolo Cinelli (UZH)

Functional Genomics Center (UZH)

Shaikh Rafeek (ZHAW)

Manfred Heller (University of Bern)

Yuguang Zhao (Wellcome Trust, Oxford)

Margaret Jones (Wellcome Trust, Oxford)



## general / financial support



FCI  
FONDS DER  
CHEMISCHEN  
INDUSTRIE



## Industrial partners

Peter Gimeson (GE Healthcare)



Daniel Weinfurtner (MorphoSys)



Thomas Müller-Späth (ChromaCon)



ChromaCon

Stefan Duhr (NanoTemper)





# Questions & Answers



**Jonas V. Schaefer**  
**[jonas.schaefer@uzh.ch](mailto:jonas.schaefer@uzh.ch)**











# Miniantibodies: construct overview

## Dimeric miniantibodies




(A) scFv-ZIP(c)

(GTCN4 leucin zipper)




(B) scFv-dHLX (-SS)

(Helix1-turn-Helix2)




## Tetrameric miniantibodies




(C) scFv-TETRAZIP

(modified GTCN4: 9 mutations)



(D) scFv-p53 (-SS)

(p53 oligomerization domain)




(E) di-bi-miniantibody

(bispecificity & bivalency)



# Miniantibodies: construct overview

Construct	Upper hinge	Self-associating peptide	Modifications
<u>Bivalent</u>			
scFv-ZIP	Murine IgG3	GCN4 leucine zipper	–
scFv-ZIPc	Murine IgG3	GCN4 leucine zipper	C-terminal Cys
scFv-dHLX	Murine IgG3	Helix1-turn-Helix2	–
scFv-dHLX-SS	Murine IgG3	Helix1-turn-Helix2	Internal Cys
<u>Bispecific</u>			
scFv-JUN	Murine IgG3	JUN leucine zipper	–
scFv-FOS	Murine IgG3	FOS leucine zipper	–
CH1-CL	Murine IgG3	CH1 and CL from IgG	–
<u>Tetravalent</u>			
scFv-TETRAZIP	Murine IgG3	GCN4 leucine zipper, modified	–
scFv-p53	Human IgG3	Oligomerization domain of human p53	–
scFv-p53-SS	Human IgG3	Oligomerization domain of human p53	Internal Cys
<u>Tetravalent/bispecific</u>			
di-bi	Murine IgG3	Helix1-turn-Helix2	–



**TETRAZIP** - exchange of all 9 hydrophobic contact positions a and d of the GCN4 zipper